Cargando…
Emerging B-Cell Therapies in Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta(®)), a fully humanized monoclonal antibody inhibiting B-cell a...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7814238/ https://www.ncbi.nlm.nih.gov/pubmed/33488082 http://dx.doi.org/10.2147/TCRM.S252592 |